Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialLisa Zimmer, Jochen Utikal, Sebastian Haferkamp et al.|The Lancet|2020Cited by 242
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trialElisabeth Livingstone, Patrick Terheyden, Lisa Zimmer et al.|The Lancet|2022Cited by 113
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trialElisabeth Livingstone, Dirk Schadendorf, Helen Gogas et al.|European Journal of Cancer|2023Cited by 15